Last reviewed · How we verify
NCT07292844
Effect of Geranium Inhalation Aromatherapy on Pain and Blood Pressure in Cancer Patients Undergoing Chemotherapy
NA trial testing Geranium Inhalation Aromatherapy in Cancer in 90 participants. Completed in 30 September 2022.
30 August 2022
Quick facts
| Lead sponsor | Universitas Muhammadiyah Surakarta |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 May 2022 |
| Primary completion | 30 August 2022 |
| Estimated completion | 30 September 2022 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Geranium Inhalation Aromatherapy
Conditions studied
- Cancer — all drugs for Cancer →
- Chemotherapy Induced Pain — all drugs for Chemotherapy Induced Pain →
- Blood Pressure Changes in Cancer Patients — all drugs for Blood Pressure Changes in Cancer Patients →
- Chemotherapy Side Effects — all drugs for Chemotherapy Side Effects →
Sponsor
Universitas Muhammadiyah Surakarta
Who can join
Adults 18 to 65, any sex, with Cancer or Chemotherapy Induced Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled trial aims to examine the effect of geranium inhalation aromatherapy on pain and blood pressure among Indonesian cancer patients undergoing intravenous chemotherapy. A total of 90 participants under the age of 65 with normal BMI will be enrolled and randomly assigned to either an intervention group or a control group. The intervention group will receive geranium essential oil inhalation using three drops applied to cotton and inhaled for 15 minutes during chemotherapy sessions, while the control group will receive usual care without aromatherapy. Pain intensity will be measured using the Visual Analog Scale (VAS), and blood pressure will be recorded using a standard digital blood pressure monitor before and after the intervention. This study aims to evaluate whether geranium aromatherapy can be feasibly implemented as a complementary supportive therapy during chemotherapy. Study Started Date after January 18, 2017
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07292844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Geranium Inhalation Aromatherapy
Trials testing the same drug.
- NCT07292831 — Geranium Inhalation Aromatherapy for Reducing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy · NA · completed
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Universitas Muhammadiyah Surakarta trials
Trials by the same sponsor.
- NCT07515677 — Digital Discharge Planning to Improve Self-Management in Patients With Diabetes Mellitus · NA · not yet recruiting
- NCT07412548 — Autogenic Relaxation and Murottal Therapy in Hemodialysis Patients · NA · not yet recruiting
- NCT07405593 — Head Up Position and Murottal Therapy in Stroke Patients · NA · not yet recruiting
- NCT07464418 — Effect of Intradialytic Eating Timing on Hemodynamic Stability and Dialysis Adequacy in Hemodialysis Patients · NA · completed
- NCT07302178 — Combined Bitter Melon Extract and Snakehead Fish Powder Supplementation for Glycemic Control in Type 2 Diabetes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07292844 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitas Muhammadiyah Surakarta
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07292844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing